Massivemarkets

Nasdaq: SGP · Listed Feb 6, 2026

SpyGlass Pharma IPO

IPO price

$16.00

SpyGlass Pharma (SGP) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 6, 2026.

SGP today$29.97+87.31%since IPO15-min delayed · as of 4:56:34 PM EST on Nov 18, 2026

See the SGP quote

First trading day · Feb 6, 2026

IPO price 16.00VWAP 26.02first trade 24.00+50.00% from the IPO pricehigh 29.81$26.80volume · rising bars above the line, falling bars below90.43K12:104:00
IPO price
$16.00
inside the range of $15 to $17
First trade
$24.00
+50.00% from the IPO price
First-day last trade
$26.80
+67.50% from the IPO price, regular session
Raise
$150M
before the underwriters' option

These numbers are from the first trading day, Feb 6, 2026.

How SGP did against the market

SGP against the market, from its first trade at 12:10 ET to the last trade of the session.

SGP from its first trade
+11.67%
Against the market (QQQ)
+11.3 pts

SGP rose 11.7% from its first trade to the last trade of the session. That is 11.3 points better than the market.

Same-day moves do not show that SGP caused them. The market is QQQ, the Nasdaq-100 ETF.

The debut race

SGP against other big listings, as the percent change from each stock's own IPO price.

The first 30 trading days. Each point is the last regular-session trade of a day.

+50%+100%+150%+200%+250%IPOday 1day 5day 10day 15day 20day 25day 30Figma '25 +69.64%Reddit '24 +40.32%CoreWeave '25 +28.42%Arm '23 -3.06%Klarna '25 -7.33%SGP +62.81%

The IPO scoreboard

SGP against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

SGP against other big IPOs: the money raised, and the return from each IPO price at the first trade, at the last trade of day 1, and on day 5 and day 30.
IPORaisedFirst tradeDay 1 closeDay 1 close, as a barDay 5Day 30
SpyGlass Pharma '26$150M+50.00%+67.50%+72.59%+62.81%
Figma '25$1.22B+157.58%+252.42%+173.64%+69.64%
Circle '25$1.05B+122.58%+168.45%+278.18%+622.98%
Reddit '24$748M+38.24%+47.97%+69.90%+40.32%
Arm '23$5.23B+10.00%+23.76%+3.63%-3.06%
Klarna '25$1.37B+30.00%+16.14%+13.73%-7.33%
CoreWeave '25$1.5B-2.50%+0.02%+34.32%+28.42%

Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.

The offering

The SpyGlass Pharma IPO offers 9.38M shares to raise $150M, before any underwriters' option.

$13$15$16$17$19
Expected price range
$15 to $17
IPO price
$16.00
Shares offered
9.38M
Money raised
$150M
Listing date
Feb 6, 2026
Exchange
Nasdaq
Security
Ordinary Shares

Money raised, against the largest IPOs

  • Alibaba '14$21.77B
  • Facebook '12$18.41B
  • Rivian '21$11.93B
  • Uber '19$8.1B
  • Arm '23$5.23B
  • SpyGlass Pharma$150M

Where SGP ranks

SpyGlass Pharma's market cap against the largest US-listed companies.

Market cap, against the largest US-listed companies

  • AAPL$5.12T
  • MSFT$3.77T
  • NVDA$3.65T
  • GOOGL$3.47T
  • AMZN$2.9T
  • TSM$1.88T
  • AVGO$1.69T
  • META$1.58T
  • TSLA$1.52T
  • BRK.B$1.22T
  • SGP$993.14M

SGP news

The latest news and headlines about SpyGlass Pharma (SGP).

Filings and the company

What SpyGlass Pharma has disclosed to the SEC, and the basic facts about the listing.

8-K filings

Material events that SpyGlass Pharma discloses to the SEC on Form 8-K.

  • Quarterly earningsNov 12, 2026

    On November 11, 2026, SpyGlass Pharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.

  • On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System.

  • Acquisition completionOct 1, 2026

    At the closing under the Purchase Agreement, which occurred on October 1, 2026 (the "Closing"), the Company acquired 100% of the outstanding equity securities (the "Shares") of Advanced Vision Science, Inc., a California corporation ("AVS"), from Seller (the "Acquisition"). The aggregate consideration paid by the Company at the Closing for the Shares was based on a purchase price of $13,000,000, subject to customary adjustments.

  • SpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial.

  • Executive compensation changeFeb 13, 2026

    On February 12, 2026, the Compensation Committee approved performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025, which will be paid shortly following such approval. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated 'Summary Compensation Table for Fiscal 2024 and 2025', which includes the amount of performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025 in the 'Non-Equity Incentive Plan Compensation' column.

About SpyGlass Pharma

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Ticker
SGP
Exchange
Nasdaq
Market
stocks
Type
CS
Currency
USD
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
65
Listed
Feb 6, 2026
Security
Ordinary Shares
Company website

Frequently asked questions

What was the SpyGlass Pharma IPO price?

$16.00 a share.

When did SpyGlass Pharma go public?

SpyGlass Pharma listed on Nasdaq on Feb 6, 2026 under the ticker SGP.

How much did the SpyGlass Pharma IPO raise?

$150M, before any underwriters' option.

How did SpyGlass Pharma open on its first day?

SGP first traded at $24.00, +50.00% from the IPO price of $16.00.

How did SGP close on its first day?

Its last regular-session trade was $26.80, +67.50% from the IPO price of $16.00.

What was the SGP first-day trading range?

$20.16 to $32.44 in the regular session.

How many SGP shares traded on the first day?

1.13M shares in the regular session.

How many shares did SpyGlass Pharma sell in its IPO?

9.38M shares.

How did SGP do against the market on its first day?

SGP rose 11.7% from its first trade to the last trade of the session. That is 11.3 points better than the market (QQQ, the Nasdaq-100 ETF).

What exchange is SGP listed on?

SpyGlass Pharma lists on Nasdaq under the ticker SGP.

Build with Massive

Get the SGP data behind this page

The Massive endpoint behind each section of this page
What the page showsEndpoint
Offering terms and dates/vX/reference/ipos
Price/v3/snapshot
Chart, VWAP, and the market comparison/v2/aggs/ticker/SGP/range/5/minute
Market cap/v3/reference/tickers/SGP
News/v2/reference/news
Filings/vX/disclosures

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.